SCHEMBL22978714

SCHEMBL22978714

Cc1cccc(OC(=O)N2CCCCC2)n1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
POLB P06746 1/20 0.51
SMN1; SMN2 Q16637 7/20 0.50
GAA P10253 2/20 0.50
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
MAPT P10636 4/20 0.48
HTT P42858 3/20 0.48
LMNA P02545 3/20 0.47
NPSR1 Q6W5P4 2/20 0.47
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
TSHR P16473 2/20 0.46
RXFP1 Q9HBX9 1/20 0.45
HPGD P15428 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27843360 0.95 SMN1; SMN2 (0.47) ALDH1A1POLBSMN1; SMN2GAAMEN1
SCHEMBL27042420 0.82 ALDH1A1 (0.51) ALDH1A1POLBSMN1; SMN2GAAMEN1
SCHEMBL28920094 0.81 SMN1; SMN2 (0.52) ALDH1A1POLBSMN1; SMN2GAAMEN1
SCHEMBL16372067 0.75 ALDH1A1 (0.54) ALDH1A1POLBSMN1; SMN2GAAMEN1
SCHEMBL3647432 0.73 RAB9A (0.44) ALDH1A1SMN1; SMN2MEN1KMT2ANPSR1
SCHEMBL4948074 0.73 RAB9A (0.44) ALDH1A1MEN1KMT2ALMNANPC1
SCHEMBL26132552 0.73 ALDH1A1 (0.51) ALDH1A1POLBSMN1; SMN2GAAMEN1
SCHEMBL31589528 0.72 ALDH1A1 (0.50) ALDH1A1POLBSMN1; SMN2GAAMEN1
SCHEMBL13952802 0.72 GRM5 (0.43) CYP1A2CYP3A4
SCHEMBL27792151 0.72 PARP1 (0.46) ALDH1A1MEN1KMT2ALMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021026803-A1 PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS NOVARTIS AG (CH) 2021-02-18 WO disclosed